Public research and development funding is a national budget issue with unusually direct local consequences in Cambridge. Universities, research institutes, laboratories and spinout companies all depend on a wider funding system that combines government support, research councils, charities, international programmes and private investment.
Latest official figures show the scale of that system. The Office for National Statistics reported that UK government net expenditure on research and development rose to £20.4 billion in 2024, up 11.6% from 2023. More recent government spending plans show that the Department for Science, Innovation and Technology expects to spend about £14.1 billion on R&D in 2026/27, with £9.2 billion allocated through UK Research and Innovation.
Why this matters in Cambridge
Cambridge contains a high concentration of research-intensive organisations, so changes in national funding can affect staffing, facilities, doctoral training, collaborative programmes and the ability to move discoveries toward commercial use.
Public funding is especially important for research that is scientifically valuable but too early, uncertain or long-term to attract immediate commercial finance. That includes fundamental science as well as infrastructure and shared facilities.
Research funding is not the same as startup investment
It is important to separate public R&D spending from venture capital or company fundraising. A university grant may support fundamental research, while a later spinout may raise private money to develop a product. The two can reinforce one another, but they are not interchangeable.
Recent Cambridge spinout activity demonstrates why the distinction matters. Commercialisation often begins with research supported over many years before a company exists.
The 2026/27 settlement puts more emphasis on commercialisation
The government’s 2026/27 plans include substantial UKRI funding for curiosity-driven research, strategic priorities and support for innovative companies. The wider Spending Review also created a Local Innovation Partnerships Fund intended to give local leaders a greater role in shaping research and innovation programmes.
For Cambridge, the key question is how national funding supports both excellence and translation: maintaining the fundamental research base while creating credible routes into new technologies, businesses and public benefits.
Science spending should therefore not be judged solely by the number of papers, patents or startups produced in a single year. Research capacity is cumulative. Laboratories, technical staff, datasets and specialist knowledge often take years to build and can be difficult to replace once lost.